* Artelo Biosciences Inc reported a quarterly adjusted loss of 75 cents per share for the quarter ended in June, lower than the same quarter last year, when the company reported EPS of -56 cents. The mean expectation of three analysts for the quarter was for a loss of 85 cents per share. Wall Street expected results to range from -88 cents to -83 cents per share.
* Reported revenue was zero; analysts expected zero.
* Artelo Biosciences Inc's reported EPS for the quarter was a loss of 75 cents.
* The company reported a quarterly loss of $2.43 million.
* Artelo Biosciences Inc shares had fallen by 5.6% this quarter and lost 9.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 4.5% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Artelo Biosciences Inc is $5.00 This summary was machine generated from LSEG data August 13 at 01:13 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.85 -0.75 Beat
Mar. 31 2024 -1.05 -0.78 Beat
Dec. 31 2023 -0.56 -1.04 Missed
Sep. 30 2023 -0.65 -0.83 Missed
Comments